Tag Archives: biotech industry

Endocyte awarded patent for vitamin receptor binding drug delivery conjugates

Endocyte, Inc. has been awarded a patent from the United States Patent and Trademark Office covering vitamin receptor binding anti-cancer agents. The patent, entitled “Vitamin Receptor Binding Drug Delivery Conjugates” (U.S. Patent No. 7,601,332), covers novel conjugation linkages and anti-cancer agents, including Endocyte’s EC145, which is currently in development as a potential treatment for ovarian and non-small cell lung cancers.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Oncolytics® Biotech Inc. issues 33rd U.S. patent

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) has been granted its 33rd U.S. Patent, No. 7,608,257, entitled “Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus.” The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Biotech and the flu pandemic

Biotechnology researchers are working to create new vaccination options to help stop the next big pandemic before it starts.  Join Dr. Targan of BIO’s BioBytes as he walks us through the current steps in vaccine production, and what biotechnology is doing to help create new vaccines in quicker timeframes to help meet the global demand (click link below for video). For those of you attending the 8th Annual BIO Investor Forum this week in San Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Panelists ponder when the window will open

Panelists in this afternoon’s business roundtable “Window Shopping – The Buyer’s Perspective on Today’s IPO Candidates” contemplated what it’s going to take to return to a vibrant IPO market. “What we need is public market examples of IPOs that are successful,” said Ashley Dombkowski, PhD, a managing director at MPM Capital. Daniel Lyons, PhD, CFA, an equity research analyst at Janus Capital added that having a lack of opportunities can make a company stand out Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Healthcare reform: sustaining biotech innovation in a new world

The Eighth Annual BIO Investor Forum kicked off today with a plenary session on health care reform with expert panelists who are entrenched in the day-to-day debate of the most comprehensive changes ever proposed for the U.S. health care system. Panelists agreed that it’s been a long and complicated debate and the end of year deadline is ambitious yet within the realm of possibility. Michelle Easton, a partner at Tarplin, Downs and Young, LLC, asserted that Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,